Trial Profile
NEO-RIT - Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced KRAS Wildtype Rectal Cancer (Clinical Stages II and III).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Rectal cancer
- Focus Therapeutic Use
- Acronyms NEO-RIT
- Sponsors Wissenschaftlicher Service Pharma
- 15 Nov 2017 Results published in the International Journal of Radiation Oncology, Biology, Physics
- 15 Nov 2017 Status changed from active, no longer recruiting to completed, according to results published in the International Journal of Radiation Oncology, Biology, Physics.
- 12 Jan 2016 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016 as per ClinicalTrials.gov record.